A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
This study has been terminated.
( Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action. )
Study NCT00363636
Information provided by Biogen Idec
First Received on August 11, 2006.
Last Updated on March 17, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
